2024.06.25
Recently, Guangzhou Wondfo Biotech Co., Ltd. ("Wondfo Biotech", stock code: 300482) issued 27,450,980 A shares to specific targets at an issuance price of RMB 25.50 per share. The shares were successfully listed on the GEM of the Shenzhen Stock Exchange and Wondfo Biotech raised approximately RMB 700 million.
Wondfo Biotech specializes in vitro diagnostics in the medical device segment. The company specializes in the research and development, manufacturing, marketing and service of point-of-care testing devices, rapid diagnostic reagents and supporting instruments. Its products are sold to more than 140 countries and regions around the world and are widely used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement and personal health management. Wondfo Biotech is one of the leading Point of Care (POCT) companies in China.
JunHe was the legal counsel for this deal and provided professional, efficient and comprehensive legal services during the entire process. This included conducting legal due diligence on Wondfo Biotech, reviewing the transaction documents and issuing legal opinions, lawyer’s work reports and other legal documents. They also provided legal analysis and submitted replies to the legal issues raised by the regulatory authorities during the review process. JunHe won the high recognition and trust of the client and the other intermediaries with its consistently rigorous and efficient work style.
Partner AN, Ming led JunHe’s team for this deal. Lawyers Joe Wan and ZHU, Yuanyuan primarily undertook the work with support for the internal review from partner CHEN, Xunan.
